why choose us

First received: August 30, 2023

Clinical Trial: A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms

Study Status: Completed

Recruit Status: RECRUITING

Condition: Myeloproliferative Neoplasms

Study Type: INTERVENTIONAL


Official Title: A Phase 1, Open-Label, Multicenter Study of INCA033989 in Participants With Myeloproliferative Neoplasms

Brief Summary: This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered in participants with myeloproliferative neoplasms.

Read more